Double attack on advanced liver cancer shows promise
NCT ID NCT03211416
Summary
This study tested whether using two drugs together works better than one for treating advanced liver cancer that has spread. The trial combined sorafenib, a pill that blocks cancer cell growth, with pembrolizumab, an IV drug that helps the immune system fight cancer. It involved 37 adults with advanced liver cancer to see if the combination was safe and could shrink tumors or slow their progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ADULT HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Robert H Lurie Comprehensive Cancer Center
Chicago, Illinois, 60611, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.